摘要
目的:探讨蒲地蓝消炎口服液联合雷贝拉唑钠肠溶胶囊,克拉霉素缓释片,盐酸左氧氟沙星片联合用蒲地蓝消炎口服液根除幽门螺杆菌(Helicobacter pylori,H.pylori)的临床疗效.方法:通过筛选自2012-04/2013-03经电子胃镜的快速尿素酶试验或14C呼气试验检验为H.pylori感染阳性的门诊患者,共观察129例,随机分为对照组和治疗组.对照组予雷贝拉唑钠肠溶胶囊10mg,2次/d,口服,克拉霉素缓释片500mg,2次/d,口服,盐酸左氧氟沙星片0.4g,2次/d,口服.治疗组加用蒲地蓝消炎口服液10mL,2次/d,口服.疗程共14d,停药30d后,评估两组疗效.结果:按意向性分析(intention-to-treat)和符合治疗方案分析(per-protocol)三联疗法联合蒲地蓝消炎口服液组和对照组H.pylori根除率分别为71.4%、73.8%和51.5%、55.7%.两组比较差异有统计学意义.症状改善方面,治疗组明显高于对照组.不良反应发生方面两组间差异无统计学意义.结论:蒲地蓝消炎口服液联合三联药物根除H.pylori效果明显,提高症状改善率,不增加不良反应的发生,值得临床推广.
AIM： To assess the clinic efficacy of Pudilan Oral Solution combined with triple therapy （rabeprazole sodium, clarithromycin and levofloxacin hydrochloride） in eradicating Helicobacter pylori （H. pylori）. METHODS： One hundred and twenty-nine patients who were diagnosed with H. pylori infection by rapid urease test or 14 C breath test from April 2012 to February 2013 were included in this study and randomly divided into either a control group or a treatment group. The control group was orally given 10 mg of rabeprazole sodium enteric-coated capsules, twice daily, 500 mg of clarithromycin extended-release tablets, twice daily, and 0.4 g of levofloxacin hydrochloride tablets, twice daily. The treatment group was additionally given 10 mL of Pudilan Oral Solution, twice daily. The patients in both groups were treated for 14 d. Clinical efficacy was assessed 30 d after the end of treatment.RESULTS： Both intention-to-treat （ITT） analysis and per-protocol （PP） analysis revealed that the rates of H. pylori eradication were significantly higher in the combination group than in the control group （ITT： 71.4% vs 51.5%; PP： 73.8% vs 55.7%, both P 0.05）. The rate of symptom improvement was also significantly higher in the treatment group than in the control group, although there was no significant difference in the incidence of adverse events between the two groups. CONCLUSION： Pudilan Oral Solution combined with triple therapy has significantly higher rates of H. pylori eradication and clinical symptom improvement than triple therapy alone, although there is no significant difference in the incidence of adverse events between the two therapies.
出处
《世界华人消化杂志》
CAS
北大核心
2013年第18期1780-1784,共5页
World Chinese Journal of Digestology
关键词
幽门螺杆菌
三联药物
蒲地蓝
Helicobacter pylori
Triple therapy
Pudilan Oral Solution
